Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12649158rdf:typepubmed:Citationlld:pubmed
pubmed-article:12649158lifeskim:mentionsumls-concept:C0026764lld:lifeskim
pubmed-article:12649158lifeskim:mentionsumls-concept:C0205918lld:lifeskim
pubmed-article:12649158pubmed:issue2lld:pubmed
pubmed-article:12649158pubmed:dateCreated2003-7-1lld:pubmed
pubmed-article:12649158pubmed:abstractTextMultiple myeloma is a disseminated neoplasm of terminally differentiated plasma cells that is incurable with currently available therapies. Although the disease is radiosensitive, external beam radiation leads to significant toxicity due to sensitive end-organ damage. Thus, genetic approaches for therapy are required. We hypothesized that the incorporation of immunoglobulin promoter and enhancer elements in a self-inactivating (SIN) lentiviral vector should lead to specific and high-level transgene expression in myeloma cells. A SIN lentivector with enhanced green fluorescent protein (EGFP) expression under the control of a minimal immunoglobulin promoter as well as the Kappa light chain intronic and 3' enhancers transduced myeloma cell lines with high efficiency (30%-90%). EGFP was expressed at a high level in myeloma cells but silent in all nonmyeloma cell lines tested compared with the cytomegalovirus (CMV) promoter/enhancer. Transduction of myeloma cells with the targeted vector coding for the human sodiumiodide symporter (hNIS) led to hNIS expression by these cells allowing them to concentrate radioiodine up to 18-fold compared with controls. Tumor xenografts in severe combined immunodeficiency mice expressing hNIS could be imaged using iodine-123 (123I) and shown to retain iodide for up to 48 hours. These tumor xenografts were completely eradicated by a single dose of the therapeutic isotope iodine-131 (131I) without evidence of recurrence up to 5 months after therapy. We conclude that lentivectors can be transcriptionally targeted for myeloma cells and the use of hNIS as a therapeutic gene for myeloma in combination with 131I needs further exploration.lld:pubmed
pubmed-article:12649158pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649158pubmed:languageenglld:pubmed
pubmed-article:12649158pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649158pubmed:citationSubsetAIMlld:pubmed
pubmed-article:12649158pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649158pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649158pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649158pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649158pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649158pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649158pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649158pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649158pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649158pubmed:statusMEDLINElld:pubmed
pubmed-article:12649158pubmed:monthJullld:pubmed
pubmed-article:12649158pubmed:issn0006-4971lld:pubmed
pubmed-article:12649158pubmed:authorpubmed-author:MorrisJohn...lld:pubmed
pubmed-article:12649158pubmed:authorpubmed-author:RussellStephe...lld:pubmed
pubmed-article:12649158pubmed:authorpubmed-author:DiazRosa...lld:pubmed
pubmed-article:12649158pubmed:authorpubmed-author:O'ConnorMicha...lld:pubmed
pubmed-article:12649158pubmed:authorpubmed-author:DingliDavidDlld:pubmed
pubmed-article:12649158pubmed:authorpubmed-author:BergertElizab...lld:pubmed
pubmed-article:12649158pubmed:issnTypePrintlld:pubmed
pubmed-article:12649158pubmed:day15lld:pubmed
pubmed-article:12649158pubmed:volume102lld:pubmed
pubmed-article:12649158pubmed:ownerNLMlld:pubmed
pubmed-article:12649158pubmed:authorsCompleteYlld:pubmed
pubmed-article:12649158pubmed:pagination489-96lld:pubmed
pubmed-article:12649158pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:meshHeadingpubmed-meshheading:12649158...lld:pubmed
pubmed-article:12649158pubmed:year2003lld:pubmed
pubmed-article:12649158pubmed:articleTitleGenetically targeted radiotherapy for multiple myeloma.lld:pubmed
pubmed-article:12649158pubmed:affiliationMayo Clinic and Foundation, Rochester, MN, USA.lld:pubmed
pubmed-article:12649158pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12649158pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:12649158pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649158lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649158lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649158lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649158lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649158lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649158lld:pubmed